Trials / Completed
CompletedNCT00441493
Fluvastatin Versus Hepatitis C Virus
A Dose Finding Study of Fluvastatin for in Vivo Demonstration of Inhibiting Hepatitis C Replication in Patients Infected With Chronic Hepatitis C With Special Attention to the African-American Population.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 32 (planned)
- Sponsor
- Bader, Ted, M.D. · Individual
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a dose finding and efficacy trial for fluvastatin versus hepatitis C.
Detailed description
Four different oral doses of fluvastatin will be used for 14 days and the viral load of hepatitis C will be measured weekly. This has been extended to different doses for 9-12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fluvastatin |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-03-01
- Completion
- 2007-09-01
- First posted
- 2007-03-01
- Last updated
- 2012-07-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00441493. Inclusion in this directory is not an endorsement.